Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines

R J Webby, D R Perez, J S Coleman, Y Guan, J H Knight, E A Govorkova, L R McClain-Moss, J S Peiris, J E Rehg, E I Tuomanen, R G Webster, R J Webby, D R Perez, J S Coleman, Y Guan, J H Knight, E A Govorkova, L R McClain-Moss, J S Peiris, J E Rehg, E I Tuomanen, R G Webster

Abstract

Background: In response to the emergence of severe infection capable of rapid global spread, WHO will issue a pandemic alert. Such alerts are rare; however, on Feb 19, 2003, a pandemic alert was issued in response to human infections caused by an avian H5N1 influenza virus, A/Hong Kong/213/03. H5N1 had been noted once before in human beings in 1997 and killed a third (6/18) of infected people. The 2003 variant seemed to have been transmitted directly from birds to human beings and caused fatal pneumonia in one of two infected individuals. Candidate vaccines were sought, but no avirulent viruses antigenically similar to the pathogen were available, and the isolate killed embryonated chicken eggs. Since traditional strategies of vaccine production were not viable, we sought to produce a candidate reference virus using reverse genetics.

Methods: We removed the polybasic aminoacids that are associated with high virulence from the haemagglutinin cleavage site of A/Hong Kong/213/03 using influenza reverse genetics techniques. A reference vaccine virus was then produced on an A/Puerto Rico/8/34 (PR8) backbone on WHO-approved Vero cells. We assessed this reference virus for pathogenicity in in-vivo and in-vitro assays.

Findings: A reference vaccine virus was produced in Good Manufacturing Practice (GMP)-grade facilities in less than 4 weeks from the time of virus isolation. This virus proved to be non-pathogenic in chickens and ferrets and was shown to be stable after multiple passages in embryonated chicken eggs.

Interpretation: The ability to produce a candidate reference virus in such a short period of time sets a new standard for rapid response to emerging infectious disease threats and clearly shows the usefulness of reverse genetics for influenza vaccine development. The same technologies and procedures are currently being used to create reference vaccine viruses against the 2004 H5N1 viruses circulating in Asia.

Figures

Figure 1
Figure 1
Creation of haemagglutinin protein of candidate vaccine seed Haemagglutinin protein of the candidate vaccine seed (Δ213/PR8) was produced by replacing the connecting peptide of the A/Hong Kong/213/03 haemagglutinin gene with that of the A/Teal/Hong Kong/W312/97 gene.
Figure 2
Figure 2
Weight changes of ferrets infected with wildtype A/Hong Kong/213/03 or Δ213/PR8 Vertical bars show SD.
Figure 3
Figure 3
Ferret lung 3 days after infection with wildtype virus (A) and the reverse genetic virus Δ213/PR8 (B) (A) Alveoli are filled with inflammatory cells and the bronchiolar submucosa is oedematous. (B) Alveoli are free of inflammatory cells and there are a few neutrophils on the surface of the bronchiolar epithelium. Magnification ×20.

References

    1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature. 1997;389:554.
    1. Subbarao K, Klimov A, Katz J. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998;279:393–396.
    1. Shortridge KF, Zhou NN, Guan Y. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology. 1998;252:331–342.
    1. Shortridge KF, Gao P, Guan Y. Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. VetMicrobiol. 2000;74:141–147.
    1. Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ. 1969;41:643–645.
    1. Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci. 2001;356:1953–1960.
    1. Bosch FX, Orlich M, Klenk HD, Rott R. The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology. 1979;95:197–207.
    1. Bosch FX, Garten W, Klenk HD, Rott R. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. Virology. 1981;113:725–735.
    1. Kawaoka Y, Nestorowicz A, Alexander DJ, Webster RG. Molecular analyses of the hemagglutinin genes of H5 influenza viruses: origin of a virulent turkey strain. Virology. 1987;158:218–227.
    1. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol. 1999;73:9679–9682.
    1. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA. 2000;97:6108–6113.
    1. Neumann G, Watanabe T, Ito H. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA. 1999;96:9345–9350.
    1. Hoffmann E, Krauss S, Perez D, Webby R, Webster R. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine. 2002;20:3165–3170.
    1. Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P. Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci. 2001;356:1965–1973.
    1. Subbarao K, Chen H, Swayne D. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology. 2003;305:192–200.
    1. Li S, Liu C, Klimov A. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis. 1999;179:1132–1138.
    1. Liu M, Wood JM, Ellis T. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology. 2003;314:580–590.
    1. Kistner O, Barrett PN, Mundt W. Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand. 1999;98:101–110.
    1. Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand. 1999;98:93–100.
    1. Halperin SA, Smith B, Mabrouk T. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine. 2002;20:1240–1247.
    1. Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of High-Yielding Influenza A Viruses in African Green Monkey Kidney (Vero) Cells by reverse genetics. J Virol. 2003;78:1851–1857.
    1. Fouchier RA, Schneeberger PM, Rozendaal FW. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA. 2004;101:1356–1361.
    1. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003;36:1552–1561.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa